Acucela Inc. (AUCL) 9.8707 $AUCL Acucela Announ
Post# of 273242
Posted On: 09/14/2016 5:03:24 AM
Acucela Inc. (AUCL) 9.8707 $AUCL
Acucela Announces Official Name of Acucela Japan as Kubota Pharmaceutical Holdings Co., Ltd.
BusinessWire - Tue Aug 09, 6:10PM CDT
Acucela Inc. (Tokyo: 4589) (the "Company"
, a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic disorders, announced today that, with requisite shareholder approval and effective at the conclusion of the proposed triangular merger (the "Triangular Merger" , the official name of Acucela Japan Kabushiki Kaisha (the "Japan Holding Company" will become Kubota Pharmaceutical Holdings Co., Ltd. Its subsidiary, Acucela North America Inc. (the "U.S. Subsidiary" , will merge with and assume the name of Acucela Inc.
Acucela Announces Top-Line Results from Phase 2b/3 Clinical Trial of Emixustat
BusinessWire - Wed May 25, 5:47PM CDT
Acucela Inc. (Tokyo: 4589) ("Acucela" , a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today top-line results from the Phase 2b/3 clinical trial (S.E.A.T.T.L.E. study) of the investigational visual cycle modulator emixustat hydrochloride (emixustat).
Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy
BusinessWire - Sun May 08, 6:36PM CDT
Acucela Inc. (Tokyo: 4589) ("Acucela" , a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today that the company initiated a phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT02753400) with the successful enrollment of the first patient, to assess the benefits of emixustat hydrochloride (emixustat) for the treatment of proliferative diabetic retinopathy (PDR).
Acucela to Present at ARVO 2016 Annual Meeting's Education Courses in Seattle
BusinessWire - Thu Apr 21, 6:36PM CDT
Acucela Inc. (Tokyo: 4589) ("Acucela" , a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today that Dr. Ryo Kubota, MD, PhD, and Chairman, President and CEO of Acucela will present at the Education Courses associated with The Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting being held May 1-5, 2016 in Seattle, WA.
Acucela Licenses Gene Therapy from The University of Manchester for Retinal Degenerative Disease
BusinessWire - Mon Apr 04, 6:40PM CDT
Acucela Inc. (Tokyo: 4589) ("Acucela" , a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, and The University of Manchester, UK ("UoM" , announced today an exclusive license agreement whereby Acucela will develop and commercialize UoM's human rhodopsin based optogenetic gene therapy(1) for the treatment of retinal degenerative disease, including Retinitis Pigmentosa ("RP" .
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.55 (+0.06), ISIS: 57.56 (-0.28), ONCE: 58.94 (-0.87), SHPG: 191.15 (-1.16), SCMP: 12.26 (-0.24), GNST: (), CLBS: 4.72 (-0.08)
Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 53.61 (-0.75), FOMX: 10.30 (+0.13), GNST: (), GSK: 42.51 (-0.79), ALIM: 1.49 (-0.02), ALXN: 126.79 (-2.50), CBIO: 1.30 (+0.07), NVS: 79.12 (-1.16)
Acucela to Present at the Biotech Showcase(TM) 2016 in San Francisco
BusinessWire - Mon Jan 11, 10:56AM CST
Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that Ryo Kubota, MD, PhD, Chairman, President and CEO, will present this week at the 8th Annual Biotech Showcase(TM) 2016 in San Francisco, CA.
Diabetic Retinopathy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - BCN Peptides, S.A. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - Dynamis Therapeutics, Inc. - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - Lpath, Inc. - Others (20) For more information visit http://www.researchandmarkets.com/research/kr3mll/diabetic
GTXI: 0.77 (unch), LPTN: 2.74 (+0.03)
Diabetic Macular Edema Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/nznc34/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aciont Inc. - ActiveSite Pharmaceuticals, Inc. - Acucela Inc. - Aerpio Therapeutics, Inc. - Allergan Plc - Ampio Pharmaceuticals, Inc. - Astellas Pharma Inc. - Avalanche Biotechnologies, Inc. - Chengdu Kanghong Pharmaceuticals Group Co., Ltd. - Chong Kun Dang Pharmaceutical Corp. - Dyax Corp. - EyeGate Pharmaceuticals, Inc. - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Kowa Company, Ltd. - Mabion SA - MacuCLEAR, Inc. - NicOx S.A. - Oculis ehf - Ohr Pharmaceutical Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SciFluor Life Sciences, LLC - Senju Pharmaceutical Co., Ltd. - ThromboGenics NV - Verseon Corporation For more information visit http://www.researchandmarkets.com/research/nz...ic_macular
PFE: 34.04 (-0.61), AMPE: 0.86 (-0.04), DYAX: 38.04 (-0.37), AGN: 240.10 (-0.13), EYEG: 1.56 (-0.12), AAVL: 4.14 (-0.18), OHRP: 2.60 (-0.03), REGN: 390.99 (-8.52)
Acucela Validates Sampling Method That Could Pave Way for More Efficient Clinical Tests
BusinessWire - Wed Nov 04, 11:00AM CST
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, has validated an analytical method that could lead to significant cost savings in the collection of blood samples as part of the company's clinical trials of emixustat hydrochloride (emixustat), the company announced today.
Global Retinopathy Of Prematurity Pipeline Review 2015 - 6 Companies & 8 Drug Profiles
M2 - Mon Oct 05, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fkn3g7/retinopathy_of) has announced the addition of the "Retinopathy Of Prematurity - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Biomar Microbial Technologies - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Insmed Incorporated Drug Profiles - aganirsen - EG-Mirotin - emixustat hydrochloride - IB-09A0133 - mecasermin rinfabate (recombinant) - R-200 - ranibizumab - Small Molecule for Retinopathy of Prematurity For more information visit http://www.researchandmarkets.com/research/fk...nopathy_of
INSM: 13.82 (-0.04)
Dr. George Lasezkay Joins Acucela as Executive Vice President, Legal Affairs
BusinessWire - Tue Aug 25, 11:09AM CDT
Acucela Inc. (TOKYO: 4589) ("Acucela" or the "Company" , a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Dr. George Lasezkay as Executive Vice President, Legal Affairs, effective Aug. 24.
Acucela Hires Dr. Lukas Scheibler as Executive Vice President of Translational Medicine
BusinessWire - Wed Aug 05, 11:31AM CDT
Acucela Inc. (TOKYO:4589) ("Acucela" or the "Company" , a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Dr. Lukas Scheibler as Executive Vice President of Translational Medicine.
NVS: 79.12 (-1.16)
Retinitis Pigmentosa (Retinitis) Therapeutics Pipeline Review, H1 2015 - 24 Companies & 42 Drug Profiles
M2 - Tue Jul 28, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vhmx/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - BioDiem Ltd - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - R-Tech Ueno, Ltd. - ReNeuron Group Plc - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AMRS-001 - Antibodies to Antagonize IL-6 for Retinitis - BDM-E - BNP-RP - CB-11 - ECL-1 - emixustat hydrochloride - FIB-111 - Gene Therapy for Glaucoma and Retinitis Pigmentosa - Gene Therapy for Ocular Diseases - Gene Therapy for Ophthalmology - Gene Therapy for Retinitis Pigmentosa - Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - GS-020 - GT-038 - ISISRHO-2.5Rx - KIRA-6 - NT-501 - OCU-100 - PRO-015 - proinsulin human SR - QLT-091001 - Recombinant Human Nerve Growth Factor - ReN-003 - Retinal Progenitor Cells for Ophthalmological Disorders - RGX-321 - RST-001 - SAR-421869 - SHP-630 - Small Molecule for Retinitis Pigmentosa - Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Small Molecules for CNS Disorders and Ophthalmology - Small Molecules for Retinitis Pigmentosa - Small Molecules for Retinitis Pigmentosa For more information visit http://www.researchandmarkets.com/research/p6vhmx/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.55 (+0.06), ISIS: 57.56 (-0.28), ONCE: 58.94 (-0.87), SHPG: 191.15 (-1.16), GNST: (), CLBS: 4.72 (-0.08)
Diabetic Retinopathy Therapeutics Pipeline Review, H1 2015 - 34 Companies & 50 Drug Profiles
M2 - Tue Jul 21, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fgxcs/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Aprogen, Inc. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - MacuCLEAR, Inc. - MingSight Pharmaceuticals - Molecular Design International, Inc. - OcuCure Therapeutics, Inc. - Ohr Pharmaceutical Inc. - PanOptica, Inc. - Promedior, Inc. - R-Tech Ueno, Ltd. - Resolvyx Pharmaceuticals, Inc - RestorGenex Corporation - Sirnaomics, Inc. - Stelic Institute & Co. - Stemedica Cell Technologies, Inc. - Targazyme, Inc. - ThromboGenics NV - TWi Pharmaceuticals, Inc. Drug Profiles - 49-B - A-6 - A-717 - AC-301 - AKB-9778 - ALG-1001 - AP-202 - ATL-1103 - BDM-E - Beta-LGND2 - CLT-01001 - CLT-01007 - CLT-01012 - cyclosporine - Cyndacel-M - DG-3173 - DMX-200 - Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - DT-23552 - E-1086 - EG-Mirotin - emixustat hydrochloride - FP-008 - IB-09A0133 - IMD-0354 - JP-153 - L-779976 - LCB-030110 For more information visit http://www.researchandmarkets.com/research/7fgxcs/diabetic
GTXI: 0.77 (unch), OHRP: 2.60 (-0.03)
Dry (Atrophic) Macular Degeneration Therapeutics Pipeline Review, H1 2015 - 20 Companies & 29 Drug Profiles
M2 - Thu Jul 09, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d36tg9/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Bioheart, Inc. - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Eleven Biotherapeutics Inc. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AdipoCell - APL-2 - avacincaptad pegol sodium - EBI-028 - eculizumab - emixustat hydrochloride - fluocinolone acetonide - Gene Therapy for Ocular Diseases - GS-020 - GSK-933776 - HMR-59 - ICR-14967 - lampalizumab - MA09-hRPE - MC-1101 - methotrexate - minocycline Gel - NM-9405 - NT-501 - OpRegen - OpRegen Plus - RC-1 Alpha - Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - RST-001 - Small Molecules for Age Related Macular Degeneration - Small Molecules for AMD - Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - TT-231 For more information visit http://www.researchandmarkets.com/research/d3...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 53.61 (-0.75), FOMX: 10.30 (+0.13), GNST: (), GSK: 42.51 (-0.79), ALIM: 1.49 (-0.02), ALXN: 126.79 (-2.50)
Acucela Hires Roger Girard as Chief Strategy Officer
BusinessWire - Thu Jul 02, 11:15AM CDT
Acucela Inc. (TOKYO: 4589) ("Acucela" or the "Company" , a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Roger Girard as Chief Strategy Officer.
Acucela Announces Publication of Phase 2a Clinical Trial Results for Emixustat Hydrochloride
BusinessWire - Wed Jun 03, 6:38PM CDT
Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced the publication of results from a Phase 2a clinical trial of emixustat hydrochloride (emixustat) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in the June online edition of RETINA: The Journal of Retinal and Vitreous Diseases. The lead author on the paper is Pravin U. Dugel, MD, Managing Partner, Retinal Consultants of Arizona and Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California. He was also a principal investigator of the emixustat study.
Acucela names Shintaro Asako to board
M2 - Tue May 19, 4:39AM CDT
Acucela Inc (Tokyo:4589) , a clinical-stage biotechnology company specialising in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced on Tuesday that Shintaro Asako has been nominated to stand for election to the company's board of directors at the 2015 Annual Meeting of Shareholders on 25 June 2015.
MNOV: 6.74 (-0.09)
Acucela Announces Official Name of Acucela Japan as Kubota Pharmaceutical Holdings Co., Ltd.
BusinessWire - Tue Aug 09, 6:10PM CDT
Acucela Inc. (Tokyo: 4589) (the "Company"
, a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic disorders, announced today that, with requisite shareholder approval and effective at the conclusion of the proposed triangular merger (the "Triangular Merger" , the official name of Acucela Japan Kabushiki Kaisha (the "Japan Holding Company" will become Kubota Pharmaceutical Holdings Co., Ltd. Its subsidiary, Acucela North America Inc. (the "U.S. Subsidiary" , will merge with and assume the name of Acucela Inc. Acucela Announces Top-Line Results from Phase 2b/3 Clinical Trial of Emixustat
BusinessWire - Wed May 25, 5:47PM CDT
Acucela Inc. (Tokyo: 4589) ("Acucela"
, a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today top-line results from the Phase 2b/3 clinical trial (S.E.A.T.T.L.E. study) of the investigational visual cycle modulator emixustat hydrochloride (emixustat). Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy
BusinessWire - Sun May 08, 6:36PM CDT
Acucela Inc. (Tokyo: 4589) ("Acucela"
, a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today that the company initiated a phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT02753400) with the successful enrollment of the first patient, to assess the benefits of emixustat hydrochloride (emixustat) for the treatment of proliferative diabetic retinopathy (PDR). Acucela to Present at ARVO 2016 Annual Meeting's Education Courses in Seattle
BusinessWire - Thu Apr 21, 6:36PM CDT
Acucela Inc. (Tokyo: 4589) ("Acucela"
, a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today that Dr. Ryo Kubota, MD, PhD, and Chairman, President and CEO of Acucela will present at the Education Courses associated with The Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting being held May 1-5, 2016 in Seattle, WA. Acucela Licenses Gene Therapy from The University of Manchester for Retinal Degenerative Disease
BusinessWire - Mon Apr 04, 6:40PM CDT
Acucela Inc. (Tokyo: 4589) ("Acucela"
, a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, and The University of Manchester, UK ("UoM" , announced today an exclusive license agreement whereby Acucela will develop and commercialize UoM's human rhodopsin based optogenetic gene therapy(1) for the treatment of retinal degenerative disease, including Retinitis Pigmentosa ("RP" . Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.55 (+0.06), ISIS: 57.56 (-0.28), ONCE: 58.94 (-0.87), SHPG: 191.15 (-1.16), SCMP: 12.26 (-0.24), GNST: (), CLBS: 4.72 (-0.08)
Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 53.61 (-0.75), FOMX: 10.30 (+0.13), GNST: (), GSK: 42.51 (-0.79), ALIM: 1.49 (-0.02), ALXN: 126.79 (-2.50), CBIO: 1.30 (+0.07), NVS: 79.12 (-1.16)
Acucela to Present at the Biotech Showcase(TM) 2016 in San Francisco
BusinessWire - Mon Jan 11, 10:56AM CST
Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that Ryo Kubota, MD, PhD, Chairman, President and CEO, will present this week at the 8th Annual Biotech Showcase(TM) 2016 in San Francisco, CA.
Diabetic Retinopathy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - BCN Peptides, S.A. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - Dynamis Therapeutics, Inc. - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - Lpath, Inc. - Others (20) For more information visit http://www.researchandmarkets.com/research/kr3mll/diabetic
GTXI: 0.77 (unch), LPTN: 2.74 (+0.03)
Diabetic Macular Edema Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/nznc34/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aciont Inc. - ActiveSite Pharmaceuticals, Inc. - Acucela Inc. - Aerpio Therapeutics, Inc. - Allergan Plc - Ampio Pharmaceuticals, Inc. - Astellas Pharma Inc. - Avalanche Biotechnologies, Inc. - Chengdu Kanghong Pharmaceuticals Group Co., Ltd. - Chong Kun Dang Pharmaceutical Corp. - Dyax Corp. - EyeGate Pharmaceuticals, Inc. - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Kowa Company, Ltd. - Mabion SA - MacuCLEAR, Inc. - NicOx S.A. - Oculis ehf - Ohr Pharmaceutical Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SciFluor Life Sciences, LLC - Senju Pharmaceutical Co., Ltd. - ThromboGenics NV - Verseon Corporation For more information visit http://www.researchandmarkets.com/research/nz...ic_macular
PFE: 34.04 (-0.61), AMPE: 0.86 (-0.04), DYAX: 38.04 (-0.37), AGN: 240.10 (-0.13), EYEG: 1.56 (-0.12), AAVL: 4.14 (-0.18), OHRP: 2.60 (-0.03), REGN: 390.99 (-8.52)
Acucela Validates Sampling Method That Could Pave Way for More Efficient Clinical Tests
BusinessWire - Wed Nov 04, 11:00AM CST
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, has validated an analytical method that could lead to significant cost savings in the collection of blood samples as part of the company's clinical trials of emixustat hydrochloride (emixustat), the company announced today.
Global Retinopathy Of Prematurity Pipeline Review 2015 - 6 Companies & 8 Drug Profiles
M2 - Mon Oct 05, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fkn3g7/retinopathy_of) has announced the addition of the "Retinopathy Of Prematurity - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Biomar Microbial Technologies - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Insmed Incorporated Drug Profiles - aganirsen - EG-Mirotin - emixustat hydrochloride - IB-09A0133 - mecasermin rinfabate (recombinant) - R-200 - ranibizumab - Small Molecule for Retinopathy of Prematurity For more information visit http://www.researchandmarkets.com/research/fk...nopathy_of
INSM: 13.82 (-0.04)
Dr. George Lasezkay Joins Acucela as Executive Vice President, Legal Affairs
BusinessWire - Tue Aug 25, 11:09AM CDT
Acucela Inc. (TOKYO: 4589) ("Acucela" or the "Company"
, a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Dr. George Lasezkay as Executive Vice President, Legal Affairs, effective Aug. 24. Acucela Hires Dr. Lukas Scheibler as Executive Vice President of Translational Medicine
BusinessWire - Wed Aug 05, 11:31AM CDT
Acucela Inc. (TOKYO:4589) ("Acucela" or the "Company"
, a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Dr. Lukas Scheibler as Executive Vice President of Translational Medicine. NVS: 79.12 (-1.16)
Retinitis Pigmentosa (Retinitis) Therapeutics Pipeline Review, H1 2015 - 24 Companies & 42 Drug Profiles
M2 - Tue Jul 28, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vhmx/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - BioDiem Ltd - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - R-Tech Ueno, Ltd. - ReNeuron Group Plc - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AMRS-001 - Antibodies to Antagonize IL-6 for Retinitis - BDM-E - BNP-RP - CB-11 - ECL-1 - emixustat hydrochloride - FIB-111 - Gene Therapy for Glaucoma and Retinitis Pigmentosa - Gene Therapy for Ocular Diseases - Gene Therapy for Ophthalmology - Gene Therapy for Retinitis Pigmentosa - Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - GS-020 - GT-038 - ISISRHO-2.5Rx - KIRA-6 - NT-501 - OCU-100 - PRO-015 - proinsulin human SR - QLT-091001 - Recombinant Human Nerve Growth Factor - ReN-003 - Retinal Progenitor Cells for Ophthalmological Disorders - RGX-321 - RST-001 - SAR-421869 - SHP-630 - Small Molecule for Retinitis Pigmentosa - Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Small Molecules for CNS Disorders and Ophthalmology - Small Molecules for Retinitis Pigmentosa - Small Molecules for Retinitis Pigmentosa For more information visit http://www.researchandmarkets.com/research/p6vhmx/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.55 (+0.06), ISIS: 57.56 (-0.28), ONCE: 58.94 (-0.87), SHPG: 191.15 (-1.16), GNST: (), CLBS: 4.72 (-0.08)
Diabetic Retinopathy Therapeutics Pipeline Review, H1 2015 - 34 Companies & 50 Drug Profiles
M2 - Tue Jul 21, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fgxcs/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Aprogen, Inc. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - MacuCLEAR, Inc. - MingSight Pharmaceuticals - Molecular Design International, Inc. - OcuCure Therapeutics, Inc. - Ohr Pharmaceutical Inc. - PanOptica, Inc. - Promedior, Inc. - R-Tech Ueno, Ltd. - Resolvyx Pharmaceuticals, Inc - RestorGenex Corporation - Sirnaomics, Inc. - Stelic Institute & Co. - Stemedica Cell Technologies, Inc. - Targazyme, Inc. - ThromboGenics NV - TWi Pharmaceuticals, Inc. Drug Profiles - 49-B - A-6 - A-717 - AC-301 - AKB-9778 - ALG-1001 - AP-202 - ATL-1103 - BDM-E - Beta-LGND2 - CLT-01001 - CLT-01007 - CLT-01012 - cyclosporine - Cyndacel-M - DG-3173 - DMX-200 - Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - DT-23552 - E-1086 - EG-Mirotin - emixustat hydrochloride - FP-008 - IB-09A0133 - IMD-0354 - JP-153 - L-779976 - LCB-030110 For more information visit http://www.researchandmarkets.com/research/7fgxcs/diabetic
GTXI: 0.77 (unch), OHRP: 2.60 (-0.03)
Dry (Atrophic) Macular Degeneration Therapeutics Pipeline Review, H1 2015 - 20 Companies & 29 Drug Profiles
M2 - Thu Jul 09, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d36tg9/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Bioheart, Inc. - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Eleven Biotherapeutics Inc. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AdipoCell - APL-2 - avacincaptad pegol sodium - EBI-028 - eculizumab - emixustat hydrochloride - fluocinolone acetonide - Gene Therapy for Ocular Diseases - GS-020 - GSK-933776 - HMR-59 - ICR-14967 - lampalizumab - MA09-hRPE - MC-1101 - methotrexate - minocycline Gel - NM-9405 - NT-501 - OpRegen - OpRegen Plus - RC-1 Alpha - Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - RST-001 - Small Molecules for Age Related Macular Degeneration - Small Molecules for AMD - Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - TT-231 For more information visit http://www.researchandmarkets.com/research/d3...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 53.61 (-0.75), FOMX: 10.30 (+0.13), GNST: (), GSK: 42.51 (-0.79), ALIM: 1.49 (-0.02), ALXN: 126.79 (-2.50)
Acucela Hires Roger Girard as Chief Strategy Officer
BusinessWire - Thu Jul 02, 11:15AM CDT
Acucela Inc. (TOKYO: 4589) ("Acucela" or the "Company"
, a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Roger Girard as Chief Strategy Officer. Acucela Announces Publication of Phase 2a Clinical Trial Results for Emixustat Hydrochloride
BusinessWire - Wed Jun 03, 6:38PM CDT
Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced the publication of results from a Phase 2a clinical trial of emixustat hydrochloride (emixustat) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in the June online edition of RETINA: The Journal of Retinal and Vitreous Diseases. The lead author on the paper is Pravin U. Dugel, MD, Managing Partner, Retinal Consultants of Arizona and Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California. He was also a principal investigator of the emixustat study.
Acucela names Shintaro Asako to board
M2 - Tue May 19, 4:39AM CDT
Acucela Inc (Tokyo:4589) , a clinical-stage biotechnology company specialising in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced on Tuesday that Shintaro Asako has been nominated to stand for election to the company's board of directors at the 2015 Annual Meeting of Shareholders on 25 June 2015.
MNOV: 6.74 (-0.09)
(0)
(0)Scroll down for more posts ▼